# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-24-013693
Filing Date
2024-04-29
Accepted
2024-04-29 16:15:25
Documents
7
Period of Report
2024-06-18

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM DEF 14A | gnpx20240418_def14a.htm | DEF 14A | 537900
2 |  | comppaidvsnetloss800.jpg | GRAPHIC | 87007
3 |  | comppaidvstsr800.jpg | GRAPHIC | 90007
4 |  | image1.jpg | GRAPHIC | 8709
5 |  | image2.jpg | GRAPHIC | 2293
6 |  | prox_page1.jpg | GRAPHIC | 253091
7 |  | prox_page2.jpg | GRAPHIC | 152678
| Complete submission text file | 0001437749-24-013693.txt |  | 1356574

Mailing Address 1601 TRINITY STREET, BLDG. B SUITE 3.322 AUSTIN TX 78712
Business Address 1601 TRINITY STREET, BLDG. B SUITE 3.322 AUSTIN TX 78712 512-537-7997
Genprex, Inc. (Filer) CIK: 0001595248 (see all company filings)

EIN.: 900772347 | State of Incorp.: TX | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38244 | Film No.: 24890970
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)